NYSE - Nasdaq Real Time Price • USD
Pfizer Inc. (PFE)
As of 12:33 PM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 16 | 16 | 23 | 22 |
Avg. Estimate | 0.52 | 0.44 | 2.21 | 2.73 |
Low Estimate | 0.37 | 0.35 | 2.05 | 2.26 |
High Estimate | 0.82 | 0.55 | 2.36 | 3.21 |
Year Ago EPS | 1.23 | 0.67 | 1.84 | 2.21 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 14 | 13 | 23 | 22 |
Avg. Estimate | 14.01B | 13.15B | 60.02B | 62.71B |
Low Estimate | 12.75B | 12.66B | 58.5B | 58.27B |
High Estimate | 16.46B | 13.99B | 60.89B | 65.5B |
Year Ago Sales | 16.59B | 12.73B | 58.5B | 60.02B |
Sales Growth (year/est) | -15.60% | 3.30% | 2.60% | 4.50% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.98 | 0.57 | -0.34 | -0.22 |
EPS Actual | 1.23 | 0.67 | -0.17 | 0.1 |
Difference | 0.25 | 0.1 | 0.17 | 0.32 |
Surprise % | 25.50% | 17.50% | 50.00% | 145.50% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.52 | 0.44 | 2.21 | 2.73 |
7 Days Ago | 0.5 | 0.42 | 2.08 | 2.56 |
30 Days Ago | 0.5 | 0.42 | 2.03 | 2.55 |
60 Days Ago | 0.51 | 0.45 | 2.2 | 2.72 |
90 Days Ago | 0.6 | 0.48 | 2.27 | 2.71 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 1 | -- | 2 | 2 |
Up Last 30 Days | 5 | 1 | 9 | 7 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 2 | 1 | 1 | -- |
Growth Estimates
CURRENCY IN USD | PFE | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -57.70% | -- | -- | 1.50% |
Next Qtr. | -34.30% | -- | -- | 11.40% |
Current Year | 20.10% | -- | -- | 5.20% |
Next Year | 23.50% | -- | -- | 13.40% |
Next 5 Years (per annum) | -1.33% | -- | -- | 11.09% |
Past 5 Years (per annum) | 0.52% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/15/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 |
Downgrade | Argus Research: Buy to Hold | 3/22/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/4/2024 |
Related Tickers
JNJ Johnson & Johnson
146.50
-1.37%
BMY Bristol-Myers Squibb Company
44.67
-8.58%
MRK Merck & Co., Inc.
130.00
+2.36%
LLY Eli Lilly and Company
725.57
-0.91%
ABBV AbbVie Inc.
167.31
-0.29%
GILD Gilead Sciences, Inc.
65.44
-2.44%
BIIB Biogen Inc.
199.57
-1.20%
AMGN Amgen Inc.
268.45
-1.67%
AZN AstraZeneca PLC
75.33
+5.80%
GSK GSK plc
40.88
+0.04%